ESG Report 2025

The Group has made successive progress in the ophthalmic field. Polyvinyl Alcohol Eye Drops for relieving dry eyes, as well as two anti-infective drugs – Moxifloxacin Hydrochloride Eye Drops and Levofloxacin Eye Drops – have been approved for marketing by the NMPA. The latter two are both fluoroquinolone antibiotics with a broad antibacterial spectrum and are included in the National Medical Insurance Drug List. The approval of these products further enriches the Company's product pipeline in the ophthalmic field, providing more clinical treatment options. The Group's self-developed Cefovecin Sodium and Cefovecin Sodium for Injection have obtained National Class II New Veterinary Drug Certificates. This product is a third-generation cephalosporin broad-spectrum antibiotic primarily used for the treatment of skin infections and urinary tract infections in dogs and cats caused by susceptible bacteria. The Enrofloxacin Granules submitted by the Group have been officially approved with a National Class IV New Veterinary Drug Certificate, mainly used for the treatment of respiratory tract diseases in pigs caused by susceptible bacteria. The self-developed Robenacoxib Chewable Tablets have obtained a Class II New Veterinary Drug Certificate. This product is a highly effective non-steroidal anti-inflammatory drug (NSAID) primarily indicated for the relief of pain caused by chronic inflammation such as osteoarthritis in dogs, further enriching the Company's product line in the pet healthcare field. The self-developed Polyhexamethylene Biguanide Hydrochloride Solution has obtained a Class III New Veterinary Drug Certificate. This product is a novel, highly effective, low-toxicity disinfectant widely used for water disinfection and pathogen control in aquaculture, as well as for disinfection and protection in pet clinic environments, helping to reduce the risk of cross-infection. Multiple Eye Drop Products Approved for Marketing R&D Progress of Animal Healthcare The Group's product R&D work strictly complies with national drug laws, regulations and technical guidelines. The R&D teams conduct comprehensive studies on pharmaceutical quality and bioequivalence in accordance with the technical requirements for drug marketing applications and generic drug consistency evaluation, ensuring that the drugs meet the standards of safety, efficacy and quality control. During the Year, the Group's Ceftriaxone Sodium for Injection (specifications: 1.0g; 2.0g), Cefotaxime Sodium for Injection (specifications: 1.0g; 2.0g), Amoxicillin Sodium and Clavulanate Potassium for Injection (specifications: 0.6g; 1.2g) and Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g) passed the generic drug quality and efficacy consistency evaluation. The successful passage of the consistency evaluation for the above products has further strengthened the Group's competitiveness in the market. As at the end of the Year, the Group had accumulated 35 products that have passed (including deemed to have passed) the consistency evaluation. The Group will continue to advance the generic drug consistency evaluation work, providing patients with more high-quality medication options. Consistency Evaluation of Generic Drug The United Laboratories has always upheld the mission of bringing safe and effective products to patients around the world and has actively participated in the activities of various chambers of commerce and associations to facilitate industry development and exchanges. At present, we are an executive council member of the China Chamber of Commerce for Import & Export of Medicines & Health Products (“CCCMHPIE”), assisting the chamber in promoting pharmaceutical trade and investment, serving as a bridge between the government and enterprises, connecting domestic and overseas markets and advancing the international development of China's healthcare industry. In addition, the Group is also a member organisation of the China Chemical Pharmaceutical Association and other industry bodies, actively supporting policy dialogue and industry collaboration. 8.2 Enhancing Medical Accessibility 57 The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report